Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

PURPOSE: Patients with hormone receptor–negative breast cancer generally do not benefit from endocrine-targeted therapies. However, a subset with androgen receptor (AR) expression is predicted to respond to antiandrogen therapies. This phase II study explored bicalutamide in AR-positive, estrogen re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gucalp, Ayca, Tolaney, Sara, Isakoff, Steven J., Ingle, James N., Liu, Minetta C., Carey, Lisa A., Blackwell, Kimberly, Rugo, Hope, Nabell, Lisle, Forero, Andres, Stearns, Vered, Doane, Ashley S., Danso, Michael, Moynahan, Mary Ellen, Momen, Lamia F., Gonzalez, Joseph M., Akhtar, Arooj, Giri, Dilip D., Patil, Sujata, Feigin, Kimberly N., Hudis, Clifford A., Traina, Tiffany A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4086643/
https://ncbi.nlm.nih.gov/pubmed/23965901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3327
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados